We studied the comparative in vitro activities of 10 oral antimicrobial agents against 147 aerobic and 61 anaerobic bacteria making up species in 13 genera (Staphylococcus aureus, streptococci, Eikenella corrodens, Pasteurella multocida, Haemophilus-Actinobacillus spp., M-5, EF-4, Moraxella spp., Flavobacterium Ilb, Bacteroides melaninogenicus, Bacteroides spp., Fusobacterium spp., and Peptostreptococcus spp.) that were isolated from bite wounds. Cefuroxime was generally >fourfold more active than cephalexin and cefadroxil against all aerobic isolates, including Pasteurella multocida. The fluoroquinolones were highly active against most aerobic isolates but were less active against anaerobic isolates. Ciprofloxacin was generally more active than either enoxacin or ofloxacin. Discrepancies of >30% in the interpretation of susceptibilities between break points suggested by the National Committee for Clinical Laboratory Standards and those related to oral dose peak levels (one-half to one-quarter of maximum achievable concentrations) were noted in 14% (18 of 130) of the instances.
The choice of an appropriate antimicrobial regimen for infections caused by animal and human bites poses a dilemma for clinicians. Approximately 80% of bite wounds harbor potential pathogens, including many unusual and fastidious aerobic and anaerobic bacteria (10) . Anaerobic bacteria can be isolated from approximately 30 and 60% of animal and human bite wounds, respectively (2, 6, 7, 10) , and their isolation has been associated with more severe clinical infections (11) . Yet, in an era of cost-consciousness, these wounds are often not cultured aerobically and are rarely cultured anaerobically except in research studies. To compound these problems, most clinical laboratories are unable to determine the in vitro susceptibilities of fastidious aerobic and anaerobic bacteria that are frequently isolated from bite wounds.
Consequently, clinicians must sometimes rely on the medical literature to guide therapeutic choices, both empiric and specific. Only two systematic susceptibility studies with large numbers and varieties of bite pathogens exist in the English language literature (2, 9) . In these studies both a high percentage of 3-lactamase-producing bacteria (2) and the emergence of bacteria that are resistant to commonly used antimicrobial agents have been noted in several genera of isolates obtained from bite wounds (9) . Information about newer alternative therapeutic agents and their in vitro activities against the full spectrum of species isolated from bite wounds is therefore needed to help guide clinicians.
Cefuroxime axetil, the new orally administered, esterified formulation of cefuroxime, and ciprofloxacin, an oral fluoroquinolone antibacterial agent, have recently been approved for use in skin and soft tissue infections. Ofloxacin and enoxacin are two other oral fluoroquinolones under investigation that have potential use in skin and soft tissue infections. Since these agents can be used to treat animal and human bite wound infections, we determined the comparative susceptibilities of 147 aerobic and 61 anaerobic bite * Corresponding author.
wound isolates to these new antimicrobial agents and compared their activities with the activities of the older antimicrobial agents that are frequently used to treat bite wound infections.
MATERIALS AND METHODS
All bacteria studied were clinical isolates and were identified by standard criteria (1, 13, 14, 17) . The sources and numbers of isolates were as follows: dog bites, 81; cat bites, 33; human bites, 53; other animal bites, 4; and bites of unknown origin, 20. Eighteen Flavobacterium Ilb isolates came from the collection of John M. Pickett (University of California, Los Angeles) and were from unknown clinical sources. The numbers and species of the isolates tested are given in Tables 1 and 2 Strains were taken from frozen stock cultures and transferred twice to ensure purity and good growth. Aerobic bacteria were tested by standard procedures by the appropriate methods for the particular organism (9, 14) . MuellerHinton agar supplemented with hemin (10 ,ug/ml) was the basal medium used for all aerobic isolates. The media for Eikenella corrodens and the viridans group streptococci were supplemented with 5% sheep blood, while media for Haemophilus spp., Actinobacillus spp., and II-J were supplemented with 5% rabbit blood. Anaerobic bacteria were cultured and inocula were prepared by the methods outlined in the Wadsworth Anaerobic Bacteriology Manual (17) . Brucella agar supplemented with hemin, vitamin K1, and 5% 100 (8) 100 (8) 100 (8) 15 (-O.1) 100 (4, 2c) 20 (<0.2) 85 (4) 100 (1) 100 (2) 100 (2) 71 (8) 6 (8) 0 (8) 94 (2) 100 (8, 4) 88 (2) 88 (4) 100 (1) 100 (2) 100 (2) 100 (8) 100 (8) 85 (8) 100 (2) 100 (8, 4) 100 (2) 100 (4) 100 (1) 100 (2) 100 (2) 100 (8) 93 (8) 64 (8) 100 (2) 100 (4, 2) 100 (2) 100 (4) 100 (1) 100 (2) 100 (2) 100 (8) 100 (8) 50 (8) 100 (2) 100 (8, 4) 100 (2) 100 (4) 100 (1) 100 (2) 100 (2) 77 (8) 69 (8) 100 (8) 100 (2) 100 (8, 4) 100 (2) 100 (4) 100 (1) 100 (2) 100 (2) 100 (2) 25b (2) 20b (2) 15 (-O.1) 100 (4, 2C) 20 (<0.2) 85 (2) 100 (1) 100 (2) 100 (2) 6b (2) 0 (2) 0 (2) 94 (2) 100 (4, 2) 88 (2) 7b (2) 100 (1) 100 (2) 100 (2) 100 (2) 40b (2) 5b (2) 100 (1) 100 (4, 2) 100 (2) 100 (2) 100 (1) 100 (2) 100 (2) 100 (2) 36b (2) 14b (2) 100 (1) 100 (4, 2) 100 (2) 71b (2) 100 (1) 100 (2) 100 (2) 100 (2) ob (2) ob (2) 100 (1) 100 (4, 2) 100 (2) 100 (2) 100 (1) 100 (2) 100 (2) 77 (2) 15b (2) 8b (2) 92 (1) Tables 1 and 2 . In addition to reporting the MICs for 50 and 90% of strains tested for each species, we also report the percentage of isolates that were susceptible at the National Committee for Clinical Laboratory Standards (NCCLS) recommended break point (R. N. Jones, Antimicrob. Newsl. 31: [1] [2] [3] [4] [5] [6] [7] [8] 1986 ) and at a break point representing one-half to one-quarter of the achievable peak concentrations in serum following a usual maximum oral dose of the antimicrobial agent (14, 15) . Discrepancies between the two break points occurred with some drugs, because the NCCLS standards are often based on levels of an agent that are achieved after parenteral administration, and we were interested in the levels that related to oral doses since most bite wounds are treated with oral antimicrobial agents. A total of 18 (14%) discrepancies of >30% in the interpretation of the susceptibilities of isolates are indicated in Tables 1 and 2. On a weight basis, cefuroxime was generally >fourfold more active than cephalexin and cefadroxil against all aerobic isolates (8 of 10 species), except for Flavobacterium IlIb isolates, for which the MICs of all three cephalosporin (8) 100 (8) 100 (8) 75 (2) 100 (8, 4C) 88 (2) 94 (4) 94 (1) 100 (2) 19 (2) 94 (8) 94 (8) 100 (8) 88 (2) 100 (8, 4) 88 (2) 82 (4) 82 (1) 94 (2) 12 (2) 100 (8) 100 (8) 100 (8) 100 (2) 100 (8, 4) 83 (2) 100 (4) 33 (1) 50 (2) 6 (2) 100 (8) 60 (8) 60 (8) 100 (2) 100 (8, 4) 100 (2) 60 (4) 80 (1) 80 (2) 20 (2) 69b (2) 100 (2) 100 (2) 69 (1) 100 (4, 2c) 88 (2) 88 (2) 94 (1) 100 (2) 19 (2) 88 (2) 76 (2) 88 (2) 82 (1) 100 (4, 2) 88 (2) 82 (2) 82 (2) 94 (2) 12 (2) 100 (2) 100 (2) 100 (2) 100 (1) 100 (4, 2) 83 (2) 100 (2) 33 (1) 50 (2) 6 (2) 80 (2) 50 (2) 60 (2) 100 (1) 100 (4, 2) 100 (2) 50 (2) 80 (1) 80 (2) 20 (2) ANTIMICROB. AGENTS CHEMOTHER.
on August 27, 2017 by guest http://aac.asm.org/ Downloaded from of other non-Bacteroides fragilis species in the genus Bacteroides. The fusobacteria and peptostreptococci tested were all susceptible to penicillin G. Amoxicillin-clavulanic acid was active against all aerobic and anaerobic isolates at <1 ,ug/ml. It was not active against Flavobacterium Ilb, which was generally resistant. Tetracycline was generally active against all aerobic genera and many of the anaerobic genera tested. The three strains of II-J tested (data not shown) were generally susceptible to all the agents tested. DISCUSSION While some clinicians advocate the use of oral cephalosporins such as cephalexin or cefadroxil for bite wounds (4), clinical failures are increasingly reported (5, 12, 18) . Several in vitro studies, including this one, have noted a high percentage of resistance of bacterial species typically found in bite wounds (2, 8, 9, 16) . Weber et al. (18) have noted that cephalexin and cefaclor do not achieve levels in blood that are sufficient to treat Pasteurella multocida infections reliably. In contrast, based on its in vitro activity against clinical isolates, cefuroxime appears to have potential clinical utility in the therapy of bite wounds. Cefuroxime was generally fourfold more active than cephalexin and cefadroxil, resulting in what should be inhibitory concentrations at a clinically achievable level. In mixed aerobic-anaerobic bite wound infections, either susceptibility studies should be performed when cefuroxime is used or clinical response should be watched carefully, since some anaerobic bacteria have been found to be resistant to cefuroxime.
In 18 of 130 (14%) instances, there were discrepancies of >30% in the susceptibility interpretation between the NCCLS criteria (Jones, Antimicrob. Newsl.) and those based on achievable oral levels of antimicrobial agents (14, 15) . These occurred almost exclusively with the cephalosporins, particularly cephalexin and cefadroxil. Streptococci, Haemophilus-Actinobacillus spp., M-5, Staphylococcus aureus, Moraxella spp., EF-4, and Pasteurella multocida isolates were regarded as susceptible by NCCLS criteria and resistant by oral level criteria. This underscores the importance of creating separate break points for the oral and parenteral usage of antimicrobial agents. In support of this result is our own clinical experience, which has shown that the treatment of human bite wounds and clenched fist injuries with cephalexin may lead to therapeutic failure because of the presence of a combination of viridans group streptococci and Eikenella corrodens (5; unpublished data). Since cefuroxime was considerably more active than cephalexin and cefadroxil, there were only two instances, one with a strain of Eikenella corrodens and one with a strain of Bacteroides melaninogenicus, in which discrepancies were found.
The fluoroquinolones were generally very active against all aerobic isolates, including Flavobacterium Ilb. However, they were deficient in their activities against aerobic streptococci. Streptococci are the bacteria that are most frequently isolated from bite wounds, usually in mixed cultures (10) . Their role as synergistic pathogens with Eikenella corrodens has been documented (3), while their role either as primary pathogens or as synergistic pathogens with other species remains to be evaluated. The fluoroquinolones were also relatively inactive against many anaerobic bacteria. Consequently, their use in the treatment of bite wounds is also problematic and will require additional clinical evaluations.
Resistance to penicillin G was seen in seven genera, including 31% of the Bacteroides melaninogenicus and 18% of other Bacteroides spp. This confirms the data of Brook (2) , who recovered P-lactamase-producing organisms in 41% (16 of 39) of cases, including 12 of 17 bite wounds treated with penicillin. Brook (2) has also noted that two of five Bacteroides melaninogenicus strains and one of three Bacteroides oralis strains that were isolated produced ,-lactamases. Results of a previous study from our laboratory (9) noted that all the Bacteroides species isolated from animal bite wounds were penicillin susceptible, while 47% (7 of 15) isolated from human bite wounds produced P-lactamase and were penicillin resistant. In the present study, resistance of most anaerobic bacteria to penicillin G was found in human bite wound isolates; one Bacteroides melaninogenicus isolated from a cat bite wound produced P-lactamase and was penicillin resistant.
Amoxicillin-clavulanic acid has been shown to be clinically effective in the treatment of bite wound infections (11) and is considered by some to be the drug of choice for empiric therapy. Our in vitro data confirm its activity against almost all species of bacteria found in bite wounds. We did not encounter the development of any resistance to amoxicillin-clavulanic acid in bite wound isolates, despite its extensive use for the treatment of infections in these wounds. Only Flavobacterium Ilb was resistant to amoxicillin-clavulanic acid.
Tetracycline had good in vitro activity against most isolates and, along with the expanded-spectrum agents of doxycycline and minocycline, offers potential utility as a therapeutic alternative in penicillin-allergic patients.
